SUMMARY Antibodies to dDNA, nDNA, Z-DNA, poly(dT), poly(I), poly(dG.dC), poly-(dA.dT), and total IgG and IgM were measured in five serial bleeds from 39 patients with systemic lupus erythematosus (SLE). The main findings were that those patients with renal disease form a distinct subset whose antibody levels correlate well with disease activity; antipoly(dT) antibodies showed the best overall correlation with disease activity; and discriminant functional analysis demonstrated a major improvement in correlation of disease activity with combinations of antibodies to dDNA/nDNA/Z-DNA/poly(dT) (generally 50% or more were correctly classified) than with dDNA or nDNA alone (generally less than 25% correct). Serum IgG (but not IgM) correlated significantly (p<O0O1) with six antibodies, suggesting that polyclonal activation plays a part in the development of these antibodies, though antibody cross reactivity is not excluded.
remains poorly defined or weakly associated, or both. Raised levels of anti-DNA antibodies may be found even in patients with SLE whose disease is inactive. 12 Antibodies to DNA have, however, proved the focus of considerable attention during the 30 years since they were identified.t-It6 We now describe a study of antibodies reactive with dDNA, nDNA, Z-DNA, and various synthetic polynucleotides which structurally resemble these forms of DNA in varying degrees. Our aim was to determine whether antibodies measured serially, and capable of distinguishing relatively subtle differences in epitopes, either singly or in combination, m-ay reflect disease activity in general or disease in a particular organ or system. Does detection of antibodies with a particular nucleic acid or combination of nucleic acids offer a better guide to disease activity than those antinuclear antibodies currently sought on a routine basis in patients with SLE? Patients, materials, and methods to a highly significant degree with six of the antibodies (anti-dDNA levels being the exception).
In contrast, serum IgM levels, rarely much increased, correlated to a statistically significant degree only with total IgG. Table 2 shows the relation between the individual were broadly similar (28-57% of the patients with SLE were positive). The patients with SLE categorised as severely ill had raised antibodies by all of these methods, but even among these inactive patients some positive results were reported with each technique. The implication of this report, that those patients judged severely ill were a distinct group, is to some extent confirmed in the 'renal' patients we have studied.
SLE is a heterogeneous condition both clinically and serologically. To determine whether individual antibodies could be matched to particular clinical features we selected for study patients who had relatively homogeneous disease. As is obvious from the scoring system used, however, the classification of the patients with SLE did require analysis of additional systemic features in determining disease severity. In the main, however, these were nonspecific (e.g., lymphadenopathy, fever, Raynaud's phenomenon, corticosteroid requirement) and should not have interfered with the activity assessment of disease in the most affected organ/system in any individual patient. The published work abounds with lupus clinical activity scores but very often few details of precisely how a patient was categorised and which particular manifestations (renal, joints, skin, etc.) were present at the time of the bleed are provided. The UCH/Middlesex criteria for disease activity used in this study have recently'9 been compared with a computer based index formulated by the British Isles Lupus Assessment Group (BILAG-a group of interested physicians in the Bloomsbury rheumatology group, London and in the rheumatology departments of Bath, Birmingham, and Glasgow). An 85% overlap of identification of active patients was noted between the two systems scored independently by the physicians from the four different centres. The overall inability of the assays we have studied to distinguish clinically inactive disease from mild activity is probably because of problems of sensitivity with the scoring system used.
A longstanding problem in analysing SLE has been the difficulty in knowing whether antibodies to all of the many antigens tested are cross reactive or whether they represent individual clonal expan- 
